Biopharma might be getting the pricing controls that it tried to stop.
Private price negotiation is a hallmark of the US health care system – banning rebates does not make that any less true.
Drug price inflation has slowed to crawl, but political pressure can only keep a lid on costs for so long.
Will US right-to-try legislation be a means of giving hope to terminally ill patients, or drug another way for drug regulatory standards to fall?
A recent US push to end drug rebates might improve transparency, but will do nothing to address the root cause of rising drug costs.
Biopharma companies have benefited from public funding for their early research, so do they have the right to charge high prices for these projects?
Competitive bidding, an attempt to bring down Medicare costs, might lead to higher out-of-pocket costs for patients.
The US government is trying to change the way Medicare reimburses doctors for office-administered drugs – but whether it will succeed is another story.
The FDA's shifting stance on the efficacy of PD-(L)1 drugs in first-line urothelial bladder cancer does little for those worried about the agency loosing its teeth.